Category
Bortezomib
CAS Number
1132709-16-0
Molecular Formula
C19H25BN4O4
Molecular Weight
384.24 g/mol
Synonym

[(1S)-3-methyl-1-[[(2R)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid; ((S)-3-Methyl-1-((R)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butyl)boronic acid; Bortezomib Enantiomer Impurity; (1S,2R)-Bortezomib; [(1S)-3-Methyl-1-({(2R)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl} amino)butyl]boronic Acid;B-[(1S)-3-Methyl-1-[[(2R)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid; ((S)-3-methyl-1-((R)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butyl)boronic Acid

Keywords
boron derivatives
Fine Chemicals
Enzyme inhibitors
Pharmaceutical Standards
Intermediates
Chiral standards
slide.1
Purity:

Above - 95.0%

Technical Data:

We will provide complete documentation support for every Standard Material. All analytical reports such as ¹H NMR, ¹³C NMR, Mass, FT-IR, HPLC Purity/GC Purity/QNMR Purity, Water content by KF/ Loss on Drying/TGA (Thermo-gravimetric Analysis). Certificate of Analysis with potency report. Each Standard Material SER (Structure Elucidation Report) with NMR, Mass, IR spectral interpretation. This whole analytical document can be included in eCTD, ANDA, DMF submissions to regulatory agencies.

Bortezomib (1S,2R)-isomer is a specific stereoisomer of Bortezomib defined by the spatial configuration (S at position 1 and R at position 2) of its two chiral centers. Stereochemistry is critical for bortezomib’s proteasome-inhibiting activity, as only certain configurations bind effectively to the 26S proteasome. Variations in configuration can significantly alter its biological activity and are carefully controlled in pharmaceutical manufacturing.